Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12264173-B2

Patent

Publication Date

2025-04-01

Expiration Date


Abstract

The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.

Core Innovation

The invention relates to compounds of Formula (II), or pharmaceutically acceptable salts thereof, and methods of treating viral infections and exacerbations of respiratory conditions in humans. Formula (II) is defined through a detailed set of structural substituent options for Base, including alkyl, heterocyclyl, and phenyl, with further allowed substitution at R1A, R2A, R3, R4A, R4B, R4C, R4D, R4E1, R4E2, R4F1, R4F2, R4G, and, in some embodiments, R5A and R5B.

The therapeutic scope covers Pneumoviridae virus infection, Picornaviridae virus infection, and treatment or prophylaxis of an exacerbation of a respiratory condition by a viral infection in humans. The respiratory condition is chronic obstructive pulmonary disease, with dependent refinements including respiratory syncytial virus, human metapneumovirus, and human rhinovirus.

The disclosure also describes specific Formula (II) compounds and related examples, including phosphorylated nucleoside-like compounds, phosphoramidate/phosphate alaninate derivatives, stereodefined phosphorus-containing compounds, and embedded chemical structures. The examples are presented with analytical characterization such as NMR, 31P NMR, LCMS, HPLC, and chiral separation of diastereomers.

Claims Coverage

The consolidated claim coverage includes three independent methods, each requiring administration of a therapeutically effective amount of a compound of Formula (II) or a pharmaceutically acceptable salt to a human. The independent inventive features are the treatment of Pneumoviridae infection, the treatment of Picornaviridae infection, and the treatment or prophylaxis of exacerbations of a respiratory condition by viral infection, with chronic obstructive pulmonary disease expressly identified in the respiratory-condition context.

Treating Pneumoviridae virus infection with Formula (II) compounds

A method of treating a Pneumoviridae virus infection in a human in need thereof by administering a therapeutically effective amount of a compound of Formula (II) or a pharmaceutically acceptable salt thereof.

Treating Picornaviridae virus infection with Formula (II) compounds

A method of treating a Picornaviridae virus infection in a human in need thereof by administering a therapeutically effective amount of a compound of Formula (II) or a pharmaceutically acceptable salt thereof.

Treating or prophylaxis of respiratory condition exacerbation by viral infection with Formula (II) compounds

A method for the treatment or prophylaxis of an exacerbation of a respiratory condition by a viral infection in a human in need thereof by administering a therapeutically effective amount of a compound of Formula (II) or a pharmaceutically acceptable salt thereof, with the respiratory condition identified as chronic obstructive pulmonary disease and dependent refinements specifying respiratory syncytial virus, rhinovirus, and metapneumovirus.

The claims consistently cover administration of Formula (II) compounds, or pharmaceutically acceptable salts, to humans for viral infection-related therapeutic uses. The inventive scope is differentiated by the target context: Pneumoviridae infection, Picornaviridae infection, and viral-exacerbation respiratory conditions, including chronic obstructive pulmonary disease.

Stated Advantages

Provides methods for treating Pneumoviridae virus infection in a human in need thereof.

Provides methods for treating Picornaviridae virus infection in a human in need thereof.

Provides methods for the treatment or prophylaxis of an exacerbation of a respiratory condition by a viral infection in a human in need thereof.

Allows treatment of respiratory exacerbation where the respiratory condition is chronic obstructive pulmonary disease.

Encompasses in vivo metabolic products, including novel or unobvious conversion products.

Documented Applications

Treating a Pneumoviridae virus infection in a human, including respiratory syncytial virus and human metapneumovirus.

Treating a Picornaviridae virus infection in a human, including human rhinovirus.

Treating or prophylaxis of an exacerbation of a respiratory condition by a viral infection in a human, wherein the respiratory condition is chronic obstructive pulmonary disease and the viral infection includes respiratory syncytial virus, rhinovirus, or metapneumovirus.

Pharmaceutical formulation for injectable and inhalable aerosol/dry powder delivery and other listed topical formulations for administering the described compounds.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.